Clinical Trial Update: DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Legend Biotech is conducting a Phase 1 trial of DLL3-directed CAR T-cells for extensive-stage small cell lung cancer, with inclusion of large cell neuroendocrin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large Cell Neuroendocrine Carcinoma of the Lung
• Small Cell Lung Cancer

Drugs mentioned

• DLL3-directed CAR T-cells

Snippet

Sponsor: Legend Biotech USA Inc | Conditions: Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung | Phase 1 | Status: ACTIVE_NOT_RECRUITING